Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein.
The report details the trend, potential and market size of HER2-negative breast cancer Treatment market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of HER2-negative breast cancer Treatmentmarket, defines the market attractiveness level of HER2-negative breast cancer Treatment market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of HER2-negative breast cancer Treatment industry, describes the types of HER2-negative breast cancer Treatment market, the applications of major players and the market size, and deeply analyzes the current situation of the global HER2-negative breast cancer Treatment market and the development prospects and opportunities of HER2-negative breast cancer Treatment industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global HER2-negative breast cancer Treatment market in Chapter 13.
By Player:
Pfizer
Novartis
GlaxoSmithKline
Merck
Eli Lilly
AstraZeneca
Bristol-Myers Squibb
By Type:
Chemotherapy
Surgery
Radiation
Hormonal Therapy/Endocrine Therapy
By End-User:
Hospitals
Clinics
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 HER2-negative breast cancer Treatment Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 HER2-negative breast cancer Treatment Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 HER2-negative breast cancer Treatment Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 HER2-negative breast cancer Treatment Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise HER2-negative breast cancer Treatment Market Analysis and Outlook to 2022
-
7.1 Global HER2-negative breast cancer Treatment Consumption (2017-2022)
-
7.2 United States HER2-negative breast cancer Treatment Consumption (2017-2022)
-
7.3 Europe HER2-negative breast cancer Treatment Consumption (2017-2022)
-
7.4 China HER2-negative breast cancer Treatment Consumption (2017-2022)
-
7.5 Japan HER2-negative breast cancer Treatment Consumption (2017-2022)
-
7.6 India HER2-negative breast cancer Treatment Consumption (2017-2022)
-
7.7 South Korea HER2-negative breast cancer Treatment Consumption (2017-2022)
8 Region and Country-wise HER2-negative breast cancer Treatment Market Analysis and Outlook to 2028
-
8.1 Global HER2-negative breast cancer Treatment Consumption Forecast (2022-2028)
-
8.2 United States HER2-negative breast cancer Treatment Consumption Forecast (2022-2028)
-
8.3 Europe HER2-negative breast cancer Treatment Consumption Forecast (2022-2028)
-
8.4 China HER2-negative breast cancer Treatment Consumption Forecast (2022-2028)
-
8.5 Japan HER2-negative breast cancer Treatment Consumption Forecast (2022-2028)
-
8.6 India HER2-negative breast cancer Treatment Consumption Forecast (2022-2028)
-
8.7 South Korea HER2-negative breast cancer Treatment Consumption Forecast (2022-2028)
9 Global HER2-negative breast cancer Treatment Market Outlook by Types and Applications to 2022
-
9.1 Global HER2-negative breast cancer Treatment Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Chemotherapy Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Surgery Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Radiation Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Hormonal Therapy/Endocrine Therapy Consumption and Growth Rate (2017-2022)
-
9.2 Global HER2-negative breast cancer Treatment Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
10 Global HER2-negative breast cancer Treatment Market Outlook by Types and Applications to 2028
-
10.1 Global HER2-negative breast cancer Treatment Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Surgery Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Radiation Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Hormonal Therapy/Endocrine Therapy Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global HER2-negative breast cancer Treatment Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
11 Global HER2-negative breast cancer Treatment Import and Export Analysis (Top 5 Countries)
-
11.1 Global HER2-negative breast cancer Treatment Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global HER2-negative breast cancer Treatment Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 HER2-negative breast cancer Treatment Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global HER2-negative breast cancer Treatment Market Competitive Analysis
-
14.1 Pfizer
-
14.1.1 Pfizer Company Details
-
14.1.2 Pfizer HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Pfizer HER2-negative breast cancer Treatment Product and Service
-
14.2 Novartis
-
14.2.1 Novartis Company Details
-
14.2.2 Novartis HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Novartis HER2-negative breast cancer Treatment Product and Service
-
14.3 GlaxoSmithKline
-
14.3.1 GlaxoSmithKline Company Details
-
14.3.2 GlaxoSmithKline HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 GlaxoSmithKline HER2-negative breast cancer Treatment Product and Service
-
14.4 Merck
-
14.4.1 Merck Company Details
-
14.4.2 Merck HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Merck HER2-negative breast cancer Treatment Product and Service
-
14.5 Eli Lilly
-
14.5.1 Eli Lilly Company Details
-
14.5.2 Eli Lilly HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Eli Lilly HER2-negative breast cancer Treatment Product and Service
-
14.6 AstraZeneca
-
14.6.1 AstraZeneca Company Details
-
14.6.2 AstraZeneca HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 AstraZeneca HER2-negative breast cancer Treatment Product and Service
-
14.7 Bristol-Myers Squibb
-
14.7.1 Bristol-Myers Squibb Company Details
-
14.7.2 Bristol-Myers Squibb HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Bristol-Myers Squibb HER2-negative breast cancer Treatment Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of HER2-negative breast cancer Treatment
-
Figure HER2-negative breast cancer Treatment Picture
-
Table Global HER2-negative breast cancer Treatment Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global HER2-negative breast cancer Treatment Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global HER2-negative breast cancer Treatment Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global HER2-negative breast cancer Treatment Consumption by Country (2017-2022)
-
Figure United States HER2-negative breast cancer Treatment Consumption and Growth Rate (2017-2022)
-
Table Europe HER2-negative breast cancer Treatment Consumption and Growth Rate (2017-2022)
-
Figure China HER2-negative breast cancer Treatment Consumption and Growth Rate (2017-2022)
-
Figure Japan HER2-negative breast cancer Treatment Consumption and Growth Rate (2017-2022)
-
Figure India HER2-negative breast cancer Treatment Consumption and Growth Rate (2017-2022)
-
Figure South Korea HER2-negative breast cancer Treatment Consumption and Growth Rate (2017-2022)
-
Figure Global HER2-negative breast cancer Treatment Consumption Forecast by Country (2022-2028)
-
Figure United States HER2-negative breast cancer Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe HER2-negative breast cancer Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure China HER2-negative breast cancer Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan HER2-negative breast cancer Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure India HER2-negative breast cancer Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea HER2-negative breast cancer Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Chemotherapy Consumption and Growth Rate (2017-2022)
-
Figure Global Surgery Consumption and Growth Rate (2017-2022)
-
Figure Global Radiation Consumption and Growth Rate (2017-2022)
-
Figure Global Hormonal Therapy/Endocrine Therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Surgery Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Radiation Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hormonal Therapy/Endocrine Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Table Global HER2-negative breast cancer Treatment Import by Region (Top 5 Countries) (2017-2028)
-
Table Global HER2-negative breast cancer Treatment Export by Region (Top 5 Countries) (2017-2028)
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer HER2-negative breast cancer Treatment Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis HER2-negative breast cancer Treatment Product and Service
-
Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)
-
Table GlaxoSmithKline HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline HER2-negative breast cancer Treatment Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck HER2-negative breast cancer Treatment Product and Service
-
Table Eli Lilly (Foundation Year, Company Profile and etc.)
-
Table Eli Lilly HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly HER2-negative breast cancer Treatment Product and Service
-
Table AstraZeneca (Foundation Year, Company Profile and etc.)
-
Table AstraZeneca HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca HER2-negative breast cancer Treatment Product and Service
-
Table Bristol-Myers Squibb (Foundation Year, Company Profile and etc.)
-
Table Bristol-Myers Squibb HER2-negative breast cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb HER2-negative breast cancer Treatment Product and Service
-
